The incidence of olfactory disorders treatment in the general population ranges from 5% to 20%. Post-COVID infection, many patients experience prolonged olfactory dysfunction, with symptoms persisting even a year after recovery. The World Health Organization estimates that persistent olfactory impairment affects up to 35 million individuals in Europe alone. The causes of olfactory dysfunction are multifaceted, including post-viral infections, post-traumatic injuries, allergic rhinitis, asthma, nasal obstruction, postnasal surgery, xerostomia, neurodegenerative diseases, idiopathic causes, and notably, COVID-19. Unfortunately, the rates of spontaneous recovery remain low. Only about one-third of patients regain normal function, and the likelihood of complete resolution decreases with time.
The Link Between COVID-19 and Olfactory Dysfunction
Olfactory disorders treatment is crucial for COVID-19 patients who experience long-term impairment. The virus targets the olfactory epithelium, damaging sensory neurons and disrupting normal function. COVID-19 has also been associated with neurological manifestations, indicating that inflammation triggered by the virus extends to the central nervous system (CNS). The olfactory bulb, located at the front of the brain, processes olfactory signals from sensory neurons. When the virus attacks this region, it can lead to persistent alterations in olfactory function.
Pathophysiology of Olfactory Dysfunction
Olfactory impairment in COVID-19 occurs through multiple mechanisms, including:
- Viral invasion of olfactory epithelium, targeting angiotensin-converting enzyme (ACE2) and transmembrane protease serine 2 (TMPRSS2) receptors.
- Acute and chronic inflammation in the olfactory bulb and CNS prolonging dysfunction.
- Neurological symptoms caused by viral migration through olfactory nerve pathways.
The damage inflicted upon sensory neurons and supporting cells disrupts the regenerative capacity of the olfactory epithelium, making recovery challenging. Patients suffering from anosmia (complete loss of smell) often experience qualitative olfactory distortions such as parosmia (altered odor perception) or phantosmia (perceiving odors that are not present). Long-term symptoms are more prevalent in individuals who initially experienced severe anosmia, females, and older adults. Studies estimate that over 10% of COVID-19 patients experience persistent olfactory dysfunction.
Treatment Options for Olfactory Dysfunction
Several treatments have been explored for olfactory dysfunction, including:
Olfactory Training
Patients repeatedly expose themselves to specific odors, such as cloves, lemon, eucalyptus, and rose, to stimulate neural regeneration. Early and frequent olfactory training has been shown to improve outcomes.
Vitamin A Therapy
Retinoic acid, a derivative of vitamin A, supports olfactory epithelial regeneration and is commonly used as a supplement for olfactory dysfunction.
Corticosteroids
Systemic or intranasal corticosteroids reduce mucosal inflammation, though their efficacy in olfactory dysfunction remains controversial.
Other Alternative Interventions
Ginkgo biloba, zinc, lipoic acid, caroverine, tetracycline, and phosphodiesterase inhibitors (e.g., theophylline) have been tested with inconsistent results.
Intranasal Insulin
Recent studies have evaluated intranasal insulin for post-COVID olfactory dysfunction, showing mixed success. Research indicates insulin may downregulate inflammatory mediators and modulate microglia activation, reducing neuroinflammation.
Platelet-Rich Plasma (PRP) Therapy for Olfactory Dysfunction
Platelet-rich plasma (PRP) is an autologous blood-derived concentrate rich in growth factors, cytokines, and bioactive proteins. PRP has regenerative and anti-inflammatory properties, promoting the repair of damaged tissues. Growth factors such as transforming growth factor, epidermal growth factor, and vascular endothelial growth factor play a critical role in neuronal regeneration and mucosal repair. Studies suggest that olfactory disorders treatment with PRP significantly improves sensory recovery and supports neural regeneration.
Scientific Evidence Supporting PRP Therapy
PRP has demonstrated efficacy in regenerating tissues such as the tympanic membrane, vocal cords, and facial nerves. It has also been used post-sinus surgery to enhance healing. Given that olfactory dysfunction involves both inflammation and neuronal damage, PRP presents a promising treatment approach.
Study: Efficacy of PRP for Persistent Olfactory Impairment Post-COVID-19
Journal of Rhinology, March 2024
- Objective: Evaluated the impact of PRP on post-COVID olfactory dysfunction.
- Sample Size: 254 participants across five studies.
- Conclusion: PRP significantly improved olfactory function, enhancing sensory thresholds, discrimination, and identification abilities. PRP was effective across all sensory neuronal types.
Study: PRP as a Treatment for Olfactory Dysfunction
Laryngoscope Investigative Otolaryngology, February 2020
- Conclusion: PRP is a safe treatment for olfactory dysfunction and shows promising efficacy, particularly for patients with persistent or moderate loss.
Study: PRP for COVID-19-Related Olfactory Dysfunction
European Archives of Otorhinolaryngology, December 2022
- Conclusion: PRP injections in the olfactory cleft increased olfactory thresholds one month after administration, with no reported adverse effects.
Juventix Regenerative Medical: A Leader in PRP Innovation
Juventix Regenerative Medical is a premier provider of regenerative medical solutions. Our FDA-cleared PRP kits ensure the highest standards of safety, sterility, and effectiveness. Our products are scientifically designed to produce highly concentrated platelets, eliminating red blood cells while maintaining optimal leukocyte levels for regenerative therapy.
Juventix PRP Innovations:
- LED Activator: Juventix PRP kits include an LED activator that stimulates platelet release without the need for chemical additives like calcium chloride, thrombin, or collagen. This non-chemical activation method ensures sustained growth factor release while adhering to FDA minimal manipulation standards.
- Bio-Incubator for PRF: Juventix offers a patented Bio-Incubator that transforms PRP into Injectable Platelet-Rich Fibrin (PRF). PRF, known as the second generation of platelet products, provides an anti-inflammatory microenvironment ideal for treating inflammatory conditions.
Juventix Regenerative Medical supplies a comprehensive range of products, devices, and services to support regenerative professionals. Our cutting-edge technology and experienced support staff ensure enhanced patient outcomes and increased satisfaction.
RESTORE, REVIVE, REGENERATE – JUVENTIX REGENERATIVE MEDICAL
Regenerative Regards,
Dr. Robert McGrath
